In a very recent article, Jake Berstein, reporter at ProPublica, highlights and ilustrates the raising concern about how drugs that are further investigated as potential cancer agents are chosen and therefore more specificaly why the cheep drug are hardly ever chosen.
Starting with the story of Michael Retsky (a MGHI amabassador), who pionnered the use of metronomic chemotherapy as a maintenance therapy in colon cancer on himself in 1994, Jake Berstien then interview several researchers (…)